Connecticut's Senate Bill 11, introduced on March 6, 2025, aims to establish a Canadian prescription drug importation program, a significant move to address rising medication costs for residents. The bill seeks to allow licensed wholesalers in Connecticut to import and distribute prescription drugs from approved Canadian suppliers, provided these drugs meet stringent safety and effectiveness standards set by the federal Food and Drug Administration (FDA).

Key provisions of the bill include strict compliance with federal regulations, ensuring that imported drugs do not violate patent laws and are not classified as controlled substances or other high-risk categories. The program is designed to enhance access to affordable medications while maintaining public health safety.

The introduction of Senate Bill 11 has sparked notable debates among lawmakers and stakeholders. Proponents argue that the bill could significantly lower prescription drug prices for Connecticut residents, alleviating financial burdens on families and individuals reliant on essential medications. Critics, however, express concerns about the potential risks associated with importing drugs, including the possibility of counterfeit products entering the market and the implications for local pharmacies.

If enacted, the bill is set to take effect on October 1, 2027, contingent upon federal approval of the importation program. This timeline allows for the necessary preparations and regulatory frameworks to be established. Experts suggest that successful implementation could serve as a model for other states grappling with similar issues of drug affordability.

The economic implications of Senate Bill 11 are substantial, as it could lead to increased competition in the pharmaceutical market, potentially driving down prices. Socially, the bill aims to improve health outcomes by making necessary medications more accessible to a broader population.

As Connecticut moves forward with this legislative initiative, the outcomes of Senate Bill 11 could reshape the landscape of prescription drug accessibility in the state, setting a precedent for future health policy reforms.